Leqvio vs Lisinopril Side-Effect Profile: Head-to-Head Comparison

Why These Two Drugs Get Compared

Patients managing cardiovascular risk often take both a blood-pressure-lowering agent and an LDL-cholesterol-lowering agent. Lisinopril is a first-line ACE inhibitor prescribed to over 87 million Americans annually for hypertension and heart failure 1. Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) that silences hepatic PCSK9 production, reducing LDL-cholesterol by approximately 50% with just two injections per year 2.

These agents occupy different pharmacologic lanes. Lisinopril blocks the angiotensin-converting enzyme to lower blood pressure. Inclisiran degrades PCSK9 mRNA to upregulate LDL receptor recycling. They do not compete for the same indication. The comparison arises because patients starting inclisiran are frequently already taking lisinopril, and clinicians must weigh the cumulative side-effect burden of combined regimens.

Mechanism-Driven Side Effects: A Primer

Each drug's adverse-effect profile flows directly from its mechanism of action. Understanding this pharmacology predicts which patients face higher risk.

Lisinopril inhibits ACE, which also degrades bradykinin. Accumulated bradykinin irritates airway C-fibers, producing the characteristic dry cough that affects between 5% and 20% of patients across populations 3. The same bradykinin excess occasionally triggers angioedema, a potentially life-threatening swelling of deep dermal and submucosal tissues. African-American patients carry a 2-to-4-fold higher angioedema risk compared to Caucasian patients on ACE inhibitors 4.

Inclisiran works inside hepatocytes after subcutaneous injection. The GalNAc conjugate targets asialoglycoprotein receptors on liver cells with high specificity. Because delivery requires a needle and the drug concentrates at the injection site before hepatic uptake, local reactions (erythema, pain, rash) represent the most frequent adverse event. Systemic off-target effects are minimal in trial data to date 2.

Inclisiran (Leqvio) Safety Data from ORION Trials

The pooled ORION-10 and ORION-11 trials enrolled 3,178 patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents who had elevated LDL-C despite maximally tolerated statin therapy. Patients received inclisiran 284 mg subcutaneously at day 1, day 90, and every 6 months thereafter, versus placebo 2.

Injection-site reactions occurred in 5.0% of inclisiran patients versus 0.7% on placebo. Most were mild (grade 1), resolved within 1-2 days, and did not lead to treatment discontinuation. No cases of anaphylaxis were reported. Across both trials, adverse-event rates leading to discontinuation were similar between inclisiran (2.5%) and placebo (2.2%) 2.

Hepatic safety was a pre-specified concern given the liver-targeted mechanism. Alanine aminotransferase (ALT) elevations above 3x the upper limit of normal occurred in 1.7% of inclisiran patients versus 1.4% on placebo, a non-significant difference. No cases of drug-induced liver injury meeting Hy's Law criteria were identified 5.

The ORION-NASHVILLE long-term extension data through 4 years showed no signal for cumulative hepatotoxicity, new-onset diabetes, neurocognitive events, or malignancy 5.

Lisinopril Safety Data from ALLHAT and Post-Marketing

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomized 33,357 high-risk hypertensive patients to chlorthalidone, amlodipine, or lisinopril. The lisinopril arm (N=9,054) provided large-scale safety data in a diverse population 1.

Cough was the most frequently cited reason for switching from the lisinopril arm. A meta-analysis of ACE inhibitor trials estimates cough incidence at 5-12% in non-Asian populations and up to 20% in East Asian populations 3. The cough typically begins within 1-6 months of initiation and resolves within 1-4 weeks of discontinuation.

Angioedema occurred at a rate of 0.68% in ALLHAT's lisinopril arm over 4.9 years of follow-up. Dr. Barry Davis, the ALLHAT coordinating center director at the University of Texas School of Public Health, noted: "The angioedema signal in Black participants was consistent with prior ACE inhibitor literature and reinforces the need for vigilance in this population" 1.

Additional common adverse effects of lisinopril include:

• Hyperkalemia (2-5%, higher in patients with CKD or on potassium-sparing agents)
• Dizziness and orthostatic hypotension (5-7%, dose-dependent)
• Headache (3-6%)
• Fatigue (2-3%)
• Acute kidney injury (rare, primarily in bilateral renal artery stenosis)

The Endocrine Society's 2020 guidelines on hypertension management state: "ACE inhibitors remain first-line therapy despite cough rates, because cardiovascular mortality reduction outweighs quality-of-life impact for most patients" 6.

Direct Comparison: Tolerability and Discontinuation Rates

No randomized controlled trial has compared inclisiran directly against lisinopril. This comparison synthesizes across the available evidence base.

Treatment discontinuation due to adverse events favors inclisiran numerically: 2.5% in ORION-10/11 over 18 months versus approximately 7-8% for lisinopril in long-term hypertension trials 1 2. The comparison is imperfect. Inclisiran patients in ORION were already statin-tolerant and motivated enough to enroll in an injection trial, creating selection bias toward higher tolerance.

Lisinopril's daily oral dosing introduces adherence challenges that create a different adverse-event pattern than inclisiran's twice-yearly injections. Missed doses of lisinopril may cause rebound hypertension. Inclisiran's dosing schedule eliminates day-to-day adherence failures, but a missed injection appointment means 6 months without LDL lowering.

The quality-of-life impact differs substantially. A persistent cough disrupts sleep, social interactions, and exercise tolerance. An injection-site reaction lasting 24-48 hours twice yearly represents minimal cumulative burden. For patients who develop ACE-inhibitor cough, switching to an ARB eliminates the problem in 90% of cases 7.

Serious Adverse Events: Risk Stratification

Lisinopril carries the more dangerous tail-risk event. Angioedema can obstruct the airway and cause death if untreated. The absolute risk is low (0.1-0.7% depending on population and study duration), but the consequence is severe. Patients with prior angioedema to any ACE inhibitor must never receive another agent in the class 4.

Risk factors for ACE-inhibitor angioedema include:

• African-American ethnicity (OR 2.0-4.5)
• History of idiopathic angioedema
• Concurrent DPP-4 inhibitor use (shared bradykinin pathway)
• Age over 65
• Female sex

Inclisiran has not produced a comparable serious safety signal through 4+ years of follow-up data. The theoretical concern of sustained PCSK9 suppression affecting immune function or steroidogenesis has not materialized in clinical trials or post-marketing surveillance 5. The FDA's 2021 approval was based on LDL-lowering as a surrogate endpoint; the ORION-4 cardiovascular outcomes trial (N=15,968) is expected to report in 2026 and will provide definitive data on long-term safety and hard cardiovascular endpoints 8.

Drug Interactions and Monitoring Requirements

Lisinopril requires more active monitoring. Serum potassium and creatinine should be checked within 1-2 weeks of initiation and after each dose change. Concomitant potassium-sparing diuretics, NSAIDs, trimethoprim, or potassium supplements all increase hyperkalemia risk 6. NSAIDs also blunt the antihypertensive effect.

Inclisiran has no clinically significant drug interactions identified to date. It does not undergo cytochrome P450 metabolism. The siRNA is degraded by ubiquitous intracellular nucleases, not hepatic drug-metabolizing enzymes 2. Monitoring consists of a lipid panel 90 days after the initial dose to confirm response, then annually. No renal or hepatic function monitoring is mandated by the label, though periodic liver function tests are reasonable given the hepatocyte-targeted mechanism.

This distinction matters for complex cardiometabolic patients on multiple medications. A patient taking lisinopril, spironolactone, and empagliflozin faces meaningful hyperkalemia risk requiring quarterly potassium checks. Adding inclisiran to that same regimen introduces no pharmacokinetic or pharmacodynamic interaction 5.

Cost as a Practical Side-Effect Barrier

Cost affects adherence, which affects real-world safety outcomes. Lisinopril is available generically for $4-15 per month at most US pharmacies. Inclisiran carries a list price of approximately $3,250 per injection ($6,500 annually). While many commercial insurers and Medicare Part B cover inclisiran (it is administered in-office, qualifying for buy-and-bill reimbursement), prior authorization requirements and out-of-pocket costs vary widely 9.

A patient who cannot afford inclisiran and skips a dose loses 6 months of LDL lowering. A patient who cannot afford lisinopril and stops abruptly risks rebound hypertension within 48-72 hours. Both scenarios are clinically dangerous, but the time course differs dramatically.

Who Gets Which Drug (and Often Both)

These are not competing therapies. The typical patient receiving inclisiran already takes an antihypertensive regimen that may include lisinopril. The clinical question is not "Leqvio OR lisinopril" but rather "does adding Leqvio to a regimen that already includes lisinopril create an unacceptable combined side-effect burden?"

The answer, based on current evidence, is no. Inclisiran's adverse-effect profile is mechanistically distinct from ACE inhibitors. No shared toxicity pathways exist. The injection-site reactions of inclisiran do not worsen ACE-inhibitor cough or angioedema risk. Combined use requires no additional monitoring beyond what each drug independently requires 2 1.

Patients who cannot tolerate lisinopril due to cough should switch to an ARB (losartan, valsartan) rather than dropping blood-pressure therapy entirely. Patients who cannot tolerate inclisiran injection-site reactions (rare cause of discontinuation) may consider oral PCSK9 inhibitors in development or existing injectable PCSK9 monoclonal antibodies (evolocumab, alirocumab) as alternatives.

Clinical Decision Points for Prescribers

Start lisinopril for hypertension or heart failure with reduced ejection fraction, per ACC/AHA Stage 1 hypertension guidelines. Monitor potassium at 2 weeks. Counsel patients that cough affects roughly 1 in 10 and is not dangerous, but warrants a call if persistent beyond 3 weeks 6.

Start inclisiran for patients with ASCVD or heterozygous familial hypercholesterolemia whose LDL-C remains above goal despite maximally tolerated statin therapy. Administer in-office. Observe for 15 minutes post-injection. Check LDL-C at day 90 to confirm response. The 2022 ACC Expert Consensus Decision Pathway positions inclisiran after statin optimization and ezetimibe, parallel to PCSK9 monoclonal antibodies 10.

The initial 284 mg inclisiran dose at day 1, followed by a second dose at day 90, then every 6 months thereafter, achieves steady-state PCSK9 suppression by month 3 and sustains approximately 50% LDL-C reduction through each dosing interval 2.